Market Overview

UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral on FDA Briefing

Share:
Related ISIS
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease
AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

Piper Jaffray reduced its rating on ISIS Pharmaceuticals (NASDAQ: ISIS) from Overweight to Neutral and reduced its price target from $18 to $10.

Piper Jaffray noted, "The FDA just released the briefing documents for KYNAMRO's Endocrinologic and Metabolic Drugs Advisory Committee meeting this Thursday, October 18th. The surprise in the docs has to do with questions #5 and #6 relating to "malignant fibrohistiocytic tumors" as well as "hemangiosarcomas" and "hepatocellular adenomas/ carcinomas" in mice "at clinically relevant exposures." … This represents a significant change in our view of KYNAMRO's safety profile going into the panel on Thursday and lowers the potential likelihood of a positive panel vote."

ISIS Pharmaceuticals closed at $13.15 on Monday.

Latest Ratings for ISIS

DateFirmActionFromTo
Jun 2015NeedhamReiteratesBuy
Jun 2015JP MorganMaintainsNeutral
Mar 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ISIS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters